Introduction {#s1}
============

Human enteroviruses (HEV) are members of the genus *Enterovirus* within the family *Picornaviridae*, order *Picornavirales*, and contains 4 species: HEV-A, HEV-B, HEV-C, and HEV-D [@pone.0055480-Knowles1]. Human enterovirus 85 (HEV85) belongs to the species HEV-B, which currently consists of 60 serotypes, including echovirus (ECHO, serotypes 1--7, 9, 11--21, 24--27, 29--33), coxsackievirus group A (CVA, serotypes 9), coxsackievirus group B (CVB, serotypes 1--6), recently identified HEV serotypes to be designated HEV69, HEV73--75 [@pone.0055480-Oberste1]--[@pone.0055480-Wang1], HEV77--88 [@pone.0055480-Bailly1]--[@pone.0055480-Oberste4], HEV93 [@pone.0055480-Junttila1], HEV97--98 [@pone.0055480-Oberste4], [@pone.0055480-Smura1], HEV100--101 [@pone.0055480-Oberste4], HEV106--107 [@pone.0055480-Yamashita1], HEV110 [@pone.0055480-Harvala1], and the simian enterovirus SA5. HEV-B viruses cause a variety of diseases such as acute aseptic meningitis, acute flaccid paralysis (AFP), hand, foot, and mouth disease, and acute myocarditis, and others [@pone.0055480-Zhu1]--[@pone.0055480-Starlin1].

The genome of HEV (approximately 7,450 nucleotides) is positive-sense, single-stranded, and contains a long open reading frame (ORF) flanked by a 5′-untranslated region (UTR) and a 3′-UTR. The 5′-UTR is about 740 nucleotides in length and comprises a secondary structure named the internal ribosome entry site [@pone.0055480-Alexander1] which is involved in the replication and internal initiation of translation of the genomic RNA [@pone.0055480-Svitkin1]. A single polyprotein translated from the RNA strand is first cleaved into 3 polyprotein precursors: P1, P2, and P3. The P1 protein encodes the 4 structural polypeptides, VP1--VP4, while P2 and P3 are precursors of the nonstructural proteins 2A--2C and 3A--3D, respectively. A short 3′-UTR, approximately 100 nucleotides in length, is located between the ORF and the poly (A) stretch, and comprises structural domains involved in RNA replication [@pone.0055480-Bergamini1].

HEV85 is a newly identified serotype within the species HEV-B. Its prototype strain (BAN00-10353/BAN/2000) was identified in a stool sample from a patient presenting with AFP in Bangladesh in 2000, and at present, only one nucleotide sequence of HEV85 (the complete genome sequence of the prototype strain) is available in the GenBank database [@pone.0055480-Oberste4].

In the present study, we analyzed 33 complete *VP1* nucleotide sequences (5 of which also have the complete genome sequences) of the HEV85 isolates recovered from one AFP patient and 32 of his health contacts in the Hotan and Kashgar prefectures, in the southern part of the Xinjiang Uighur autonomous region of China, in 2011. The results indicate that Chinese HEV85 strains are all recombinants with a new unknown serotype HEV-B and circulate in the southern part of Xinjiang.

Results {#s2}
=======

Transmission of HEV85 in Xinjiang in 2011 {#s2a}
-----------------------------------------

The *VP1* region nucleotide sequence alignment included all 33 Chinese HEV85 strains and the prototype strain. The pairwise distance among the 33 Chinese HEV85 strains ranged from 0.000 to 0.026 divergence, and from 0.115 to 0.128 divergence compared with the prototype strain. On the basis of the high nucleotide and amino acid identities of the *VP1* region of all 33 Chinese HEV85 isolates, strain HTYT-ARL-AFP02F, which was isolated from an AFP patient, was selected as the representative strain and depicted the scatter diagram, the plot of the amino acid sequence identity versus nucleotide sequence identity ([Figure 1](#pone-0055480-g001){ref-type="fig"}). HEV-D was omitted in this figure because few HEV-D sequences are available in the GenBank database. The plotting curve showed obvious grouping among HEV-A, HEV-B, and HEV-C, and the nucleotide and amino acid sequences of the strain HTYT-ARL-AFP02F had the lowest similarity values with HEV-A and HEV-C species. Intermediate values were observed with HEV-B species, ranging from 55.9% to 69.7% and from 57.3% to 75.2% for nucleotide and amino acid sequences, respectively ([Table 1](#pone-0055480-t001){ref-type="table"}), which confirmed it was a member of HEV-B species. Finally, there were high nucleotide and amino acid sequence similarities values (89.4% and 98.6% for the nucleotide and amino acid sequences, respectively) between strain HTYT-ARL-AFP02F and the HEV85 prototype strain.

![Scatter diagram of the amino acid sequence identity versus nucleotide sequence identity of Chinese HEV85 strain.\
Analysis of pairwise comparisons between the representative Chinese HEV85 strain, HT-LYKH202F/XJ/CHN/2011, and the prototype strains of other human enterovirus serotypes by comparison of VP1 amino acid sequence identity plotted versus *VP1* nucleotide sequence identity.](pone.0055480.g001){#pone-0055480-g001}
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###### Pairwise nucleotide and amino acid sequence identities between human enterovirus 85 strains and prototype strains of the HEV-B species.

![](pone.0055480.t001){#pone-0055480-t001-1}

  Region      Nucleotide identity (%) \[Amino acid identity (%) \]                                                                                                                                                                  
  ---------- ------------------------------------------------------ ------------------------- ------------- ------------------------- ------------- ------------------------- ------------- ------------------------- ------------- -------------------------
  *5′-UTR*                            91.5                                 79.6--88.4             91.3             79.4--88.3             91.2             79.5--88.2             91.3             79.3--88.3             91.2             79.2--88.2
  *VP4*                            89.3 (100)                        69.0--81.1 (75.3--95.6)   89.8 (100)    68.5--81.1 (75.3--95.6)   89.8 (98.5)   68.5--81.1 (75.3--94.2)   89.8 (100)    69.0--81.6(75.3--95.6)    90.3 (100)    69.0--80.6 (75.3--95.6)
  *VP2*                           89.5 (98.8)                        64.9--72.5 (75.5--83.2)   89.2 (98.4)   64.9--72.2 (75.5--83.2)   89.6 (98.8)   64.5--72.2 (75.5--83.2)   89.1 (98.8)   65.0--72.9 (75.5--83.5)   89.6 (98.4)   64.9--72.4 (75.5--83.2)
  *VP3*                           90.0 (98.7)                        63.1--71.0 (66.9--81.9)   89.9 (98.7)   63.1--71.1 (66.9--81.9)   88.9 (99.1)   63.2--70.4 (66.9--81.9)   89.3 (98.7)   62.8--70.7 (66.9--81.5)   89.9 (99.1)   63.1--70.7 (66.9--81.9)
  *VP1*                           89.4 (98.9)                        55.5--69.8 (57.3--75.6)   89.4 (98.6)   55.9--69.7 (57.3--75.2)   89.1 (98.6)   55.6--69.0 (57.0--75.6)   89.0 (97.9)   55.5--69.7 (57.0--75.2)   89.6 (98.9)   55.6--69.1 (57.3--75.6)
  *2A*                            79.3 (94.6)                        75.1--81.7 (84.6--96.0)   79.5 (94.6)   74.8--81.5 (84.6--96.0)   79.7 (94.6)   75.3--81.1 (84.6--96.0)   80.2 (95.3)   74.8--81.5 (85.3--96.6)   80.0 (94.6)   75.5--81.7 (84.6--96.0)
  *2B*                            80.1 (94.9)                        75.7--83.8 (93.9--98.9)   80.4 (94.9)   75.0--83.5 (93.9--98.9)   80.1 (94.9)   75.0--83.5 (93.9--98.9)   80.8 (94.9)   76.0--83.1 (93.9--98.9)   79.4 (94.9)   75.0--83.1 (93.9--98.9)
  *2C*                            83.8 (98.4)                        79.2--84.9 (96.3--99.0)   84.3 (98.7)   79.4--84.9 (96.6--99.3)   84.1 (99.0)   79.5--85.2 (96.9--99.6)   84.3 (98.7)   79.6--85.1 (96.6--99.3)   84.0 (97.8)   79.1--84.7 (85.7--99.0)
  *3A*                            80.1 (97.7)                        75.6--85.3 (91.0--98.8)   80.5 (97.7)   76.0--85.7 (91.0--98.8)   80.5 (97.7)   76.0--85.7 (91.0--98.8)   79.4 (97.7)   74.9--84.6 (91.0--98.8)   80.1 (97.7)   75.6--85.3 (91.0--98.8)
  *3B*                             84.8 (100)                        69.6--87.8 (90.9--100)    87.8 (100)    72.7--87.8 (90.9--100)    87.8 (100)    72.7--87.8 (90.9--100)    86.3 (100)    71.2--89.3 (90.9--100)    86.3 (100)    71.2--89.3 (90.9--100)
  *3C*                            83.9 (98.9)                        75.9--85.7 (92.8--99.4)   83.7 (98.3)   75.9--85.6 (92.3--98.9)   83.9 (98.9)   76.1--85.7 (92.8--99.4)   84.3 (98.9)   76.1--86.1 (92.8--99.4)   84.1 (98.9)   75.7--85.4 (92.8--99.4)
  *3D*                            84.9 (97.6)                        77.5--85.6 (95.0--98.2)   85.5 (98.0)   78.1--86.1 (95.4--98.8)   85.4 (97.8)   77.8--86.2 (95.2--98.4)   85.1 (97.8)   77.7--85.7 (95.2--98.4)   85.6 (98.0)   77.9--86.0 (95.4--98.7)
  *3′-UTR*                            87.5                                 74.0--91.3             87.5             75.0--91.3             88.4             74.0--92.3             87.5             73.0--91.3             88.4             74.0--92.3

Phylogenetic analysis was performed on the basis of the alignment of *VP1* region sequences described above ([Figure 2](#pone-0055480-g002){ref-type="fig"}). Clearly all 33 Chinese HEV85 strains are derived from the same origin, and a 2.0% nucleotide divergence was found among these strains. They were all circulated in the Hotan and Kashgar prefectures of southern Xinjiang from September to November 2011,

![Transmission of the Chinese HEV85 strains in Xinjiang of China.\
Phylogenetic analysis and genetic characterization of 33 Chinese HEV85 isolates. Strains indicated by the symbol • indicate HEV85 strains that were subjected to complete genome sequencing; strains indicated by the symbol ▴ indicate HEV85 strain that were subjected to the temperature sensitivity test.](pone.0055480.g002){#pone-0055480-g002}

Full-length genomic characterizations of Chinese HEV85 strains {#s2b}
--------------------------------------------------------------

The full-length genome sequences of 5 selected Chinese HEV85 strains were determined (randomly selected on the basis of their genetic relationships; [Figure 2](#pone-0055480-g002){ref-type="fig"}). The results showed that they were similar to the only reported genome of HEV85 (the prototype strain), with 7,422--7,424 nucleotides, including a 5′-UTR of 742--744 nucleotides (0--2 nucleotide insertion compared with the prototype strain), a single ORF of 6,579 nucleotides encoding a single polyprotein of 2,191 amino acids, and a 3′-UTR of 101 nucleotides preceding the poly (A) tract. All these sequences shared 98.34--99.08% nucleotide sequence identities with each other, validating the circulation of HEV85 in Xinjiang of China.

A comprehensive comparison of nucleotide sequence and deduced amino acid sequence identities between the 5 Chinese HEV85 strains and the prototype strain of HEV-B viruses including HEV85 is shown in [Table 1](#pone-0055480-t001){ref-type="table"}. The nucleotide sequence identities between the 5 Chinese HEV85 strains and the prototype HEV85 strain were 86.46--86.73% in the full-length genome sequence and 89.28--89.67%, 82.06--82.70%, and 84.15--84.68% in the *P1*, *P2*, and *P3* coding regions, respectively. The deduced amino acid sequence identities between the 5 Chinese HEV85 strains and the prototype HEV85 strain were 98.60--98.95%, 96.54%--97.23%, and 98.02--98.28% in the *P1*, *P2*, and *P3* coding regions, respectively. Interestingly, in the capsid region, the nucleotide sequences of the 5 Chinese HEV85 isolates were more closer to the HEV85 prototype strain (89.28--89.67%) than to other HEV-B prototype strains (58.8--68.3%, [Table 1](#pone-0055480-t001){ref-type="table"}); while in the noncapsid region, the nucleotide sequences of the 5 Chinese HEV85 isolates and all HEV-B viruses including HEV85 were almost equidistant from each other (74.3--81.8%) and did not cluster with regard to all known serotypes HEV-B viruses, which indicated the occurrence of recombination events in the noncapsid region.

Chinese HEV85 strains recombined with new unknown serotype HEV-B donor sequences {#s2c}
--------------------------------------------------------------------------------

Alignments of the *VP1*, *P1*, *P2*, *and P3* region nucleotide sequences were carried out among the 5 selected Chinese HEV85 strains described above and the prototype strains of HEV-B, and phylogenetic trees were constructed ([Figure 3](#pone-0055480-g003){ref-type="fig"}). The phylogenetic tree analysis suggested that Chinese HEV85 strains are monophyletic in the *VP1* region, and all 5 Chinese HEV85 strains clustered together with the HEV85 prototype stain ([Figure 3a](#pone-0055480-g003){ref-type="fig"}), confirming the classification of these isolates as a single enterovirus type. All 5 Chinese HEV85 strains clustered with the HEV85 prototype strain in the *P1* capsid region ([Figure 3b](#pone-0055480-g003){ref-type="fig"}), but not in the *P2* and *P3* noncapsid regions ([Figure 3c and 3d](#pone-0055480-g003){ref-type="fig"}), indicating that recombination occurred among Chinese HEV85 strains.

![Unrooted trees representing the phylogenetic relationships among Chinese HEV85 strains and other members of HEV-B.\
The phylogenetic trees based on nucleotide sequences for *VP1* coding sequences (a), *P1* coding sequences (b), *P2* coding sequences (c), and *P3* coding sequences (d) were constructed from the nucleotide sequence alignment using the neighbor-joining algorithm of the MEGA 5.0 software. Numbers at nodes indicate bootstrap support for that node (percent of 1000 bootstrap pseudoreplicates). The scale bars represent the genetic distance, and all unrooted trees have the same scale.](pone.0055480.g003){#pone-0055480-g003}

Similarity plot and bootscan analyses revealed recombination between the Chinese HEV85 strains and HEV-B strains at the *2A*--*2B* junction. The Chinese HEV85 strains were all identified as a HEV85 capsid sequence containing an unidentified sequence in the *P2* and *P3* coding regions that was apparently not related to those of the HEV85 strains ([Figure 4](#pone-0055480-g004){ref-type="fig"}). Nucleotide and amino acid sequences in the *P2* and *P3* regions are highly conserved within an enterovirus species [@pone.0055480-Brown1], and *P2* and *P3* sequences do not correlate with HEV serotypes due to frequent recombination; however, these sequences clearly distinguish different HEV species [@pone.0055480-Oberste4]. Comparison of the *P2* and *P3* coding region sequences of the Chinese HEV85 strains with those of certain prototype strains of HEV-A, B, C, and D revealed no sequence match above 84.68%, and showed higher similarity to HEV-B than to HEV-A, C, and D. In addition, the deduced amino acid sequence of the recombinant noncapsid sequences of the Chinese HEV85 strains showed high identity with HEV-B, especially those of prototype HEV88 (97.9%), prototype HEV75 (97.8%), and prototype HEV85 (97.6%). These results confirmed that the recombinant noncapsid sequences were classified into the HEV-B phylogeny ([Figure 4](#pone-0055480-g004){ref-type="fig"}).

![Similarity plot and bootscan analysis of whole genome of Chinese HEV85 strains.\
Gene structure organization (a), similarity plot (b), and bootscan analysis (c) of complete HEV-B genomes using a sliding window of 200 nt moving in 20 nt steps. The HTYT-ARL-AFP02F/XJ/CHN/2011 isolate was used as a query sequence and is indicated in the lower right corner, and for each bootscan analysis, the names of viruses of the query sequence are indicated in the upper right corner.](pone.0055480.g004){#pone-0055480-g004}

Because the nucleotide sequence identities between the Chinese HEV85 strain and all the HEV-B prototypes in the noncapsid region ranged from 78.63% (HEV80) to 84.30% (HEV107), the noncapsid donor sequences could not be classified as any known serotype; the donor sequences were from a new unknown serotype within HEV-B.

Temperature sensitivity {#s2d}
-----------------------

Three selected Chinese HEV85 isolates (HT-LYKH202F, HTYT-ARL-AFP01F, and HTYT-ARLH403F) were compared to each other with regard to replication capacity at an elevated temperature (39.5°C), and showed different temperature sensitivities ([Figure 5](#pone-0055480-g005){ref-type="fig"}). Strain HT-LYKH202F was temperature-sensitive with titer reduction of more than 2 logarithms at 36°C/39.5°C, whereas the other 2 strains showed definitely lower temperature sensitivities (titers reduced less than 2 logarithms at 36°C/39.5°C). This indicates that the replication efficiencies of these strains remain the same even at elevated temperatures ([Figure 5](#pone-0055480-g005){ref-type="fig"}).

![Temperature sensitivity test curves of 3 selected HEV85 isolates.\
The blue and red lines represent the growth trend of the viruses on RD cell at 36°C and 39.5°C, respectively.](pone.0055480.g005){#pone-0055480-g005}

In order to further investigate determinants of temperature sensitivity among these strains, differences in nucleotide and amino acid sequences between the temperature-sensitive strain and the 2 temperature-insensitive strains were summarized ([Table 2](#pone-0055480-t002){ref-type="table"}). The results indicate that the numbers of different nucleotides and amino acid were 46 and 6, respectively. On the basis of the above results and on many previous studies of other serotypes of HEVs [@pone.0055480-Zhang1], [@pone.0055480-Arita1], we believe that a total of 8 nucleotides in the *5′-UTR* (nt161), *2C* (nt4102 and nt4256), *3D* (nt6178, nt6340, nt6719, and nt6972), and *3′-UTR* (nt7330) regions are candidate determinant sites for temperature sensitivity in HEV85.

10.1371/journal.pone.0055480.t002

###### Sites of nucleotide and amino acid disparity between the temperature-sensitive strain HT-LYKH202F (a) and temperature-insensitive strains HTYT-ARL-AFP01F (b) and HTYT-ARLH403F (c).
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  Origin or donor                                          Region           Nucleotide   Amino acid                                                 
  ----------------------------------------------- ------------------------ ------------ ------------ ------- ------- ---------- --------- --------- ---------
  **HEV85 Sequence**                               ***5*** *′-* ***UTR***    **161**       **C**      **T**   **T**    **/**      **/**     **/**     **/**
                                                         ***VP4***            **/**        **/**      **/**   **/**    **/**      **/**     **/**     **/**
                                                         ***VP2***             989           C          T       T                                   
                                                         ***VP3***             1985          C          T       T                                   
                                                                               2174          T          C       C                                   
                                                         ***VP1***             2729          A          T       T                                   
                                                                               2915          C          T       T                                   
  **New unknown serotype HEV-B donor sequence**           ***2A***             3449          C          T       T                                   
                                                                               3551          A          G       G                                   
                                                                               3623          T          C       C                                   
                                                          ***2B***             3929          C          T       T                                   
                                                                               3953          T          C       C                                   
                                                          ***2C***           **4102**      **G**      **A**   **A**   **1120**   **Ser**   **Asn**   **Asn**
                                                                             **4256**      **T**      **A**   **A**   **1171**   **Asp**   **Glu**   **Glu**
                                                                               4565          T          C       C                                   
                                                                               4721          C          T       T                                   
                                                                               4799          T          C       C                                   
                                                                               4898          C          T       T                                   
                                                                               4910          T          C       C                                   
                                                                               4976          T          C       C                                   
                                                                               5006          T          C       C                                   
                                                          ***3A***             5081          T          C       C                                   
                                                          ***3B***             5354          G          A       A                                   
                                                                               5378          G          A       A                                   
                                                          ***3C***             5549          T          C       C                                   
                                                                               5576          C          T       T                                   
                                                                               5630          A          G       G                                   
                                                                               5645          G          A       A                                   
                                                                               5696          T          C       C                                   
                                                                               5882          A          T       T                                   
                                                          ***3D***             5999          G          A       A                                   
                                                                               6113          C          T       T                                   
                                                                             **6178**      **C**      **T**   **T**   **1812**   **Ala**   **Val**   **Val**
                                                                               6212          A          G       G                                   
                                                                               6252          T          C       C                                   
                                                                               6267          T          C       C                                   
                                                                               6284          T          G       G                                   
                                                                             **6340**      **G**      **A**   **A**   **1866**   **Arg**   **Lys**   **Lys**
                                                                               6350          T          A       A                                   
                                                                               6431          G          A       A                                   
                                                                             **6719**      **C**      **A**   **A**   **1992**   **Asp**   **Glu**   **Glu**
                                                                               6725          T          C       C                                   
                                                                               6761          T          C       C                                   
                                                                             **6972**      **A**      **G**   **G**   **2077**   **Thr**   **Ala**   **Ala**
                                                                               7175          C          T       T                                   
                                                                               7244          T          C       C                                   
                                                   ***3*** *′-* ***UTR***    **7330**      **T**      **C**   **C**    **/**      **/**     **/**     **/**

Nucleotide and amino acid positions in shadow indicate candidate determinant sites for temperature sensitivity in HEV85.

Discussion {#s3}
==========

Molecular serotyping methods have enabled the rapid identification of new HEV serotypes that are untypeable by traditional neutralization of virus isolates in cell culture using standardized antisera, and as a result, sequencing of the complete *VP1* capsid region has emerged as the gold standard for HEV typing to distinguish serotypes [@pone.0055480-Oberste5]--[@pone.0055480-Nix1]. Molecular identification of recently identified HEV serotypes, including HEV85, provides a tool to assist in the epidemiological investigation of AFP cases that are associated with non-polio enterovirus infection.

In this study, we identified 33 HEV85 isolates in the Hotan and Kashgar prefectures in the Xinjiang region in China from 6^th^ Aug to 20^th^ Sep 2011, which indicated the prevalence of this serotype of HEV in this region. These 2 prefectures are located in the southernmost part of Xinjiang and have great biological and climatic differences due to the large area (409,800 square kilometers in total), which includes the southern mountain area (temperate or cold temperate climate), the oasis plain area (warm temperate), and the northern desert area (continental desert climate). The viruses were isolated from the oasis plain area, where is very suitable for the growth and survival of HEV. HEVs are known to be propagated mainly by fecal-oral transmission, suggesting that the river, the source of water, geographic circumstances, and air humidity are major factors affecting transmission. This is confirmed by the facts that the majority of the prototype strains of novel HEV serotypes were isolated from tropical and subtropical countries and regions such as Bangladesh [@pone.0055480-Oberste4], [@pone.0055480-Oberste7], California (USA) [@pone.0055480-Oberste1], [@pone.0055480-Oberste4], Egypt [@pone.0055480-Smura2] and Cote d\'Ivoire [@pone.0055480-Oberste4], etc, while the prevalence of these viruses seems to be relatively restricted in the temperate countries.

One of the 33 Chinese HEV85 isolates, strain HTYT-ARL-AFP02F, was derived from an adult patient who presented with AFP in July 2011. Although there is no strong evidence to prove that HEV85 is the causative pathogen of AFP, as the virus was recovered from a stool specimen, it showed high transmissibility based on the fact that it has high nucleotide and amino acid identities with other Chinese HEV85 isolates picked from the contacts of this AFP patient. This strain was also temperature-insensitive and could grow at relatively high temperatures, which is usually an indicator of high virulence or transmissibility [@pone.0055480-Arita1], [@pone.0055480-Georgescu1]. These findings suggest that HEV85 is an important human pathogen; however, more data are necessary before HEV85 can be positively associated with any particular human disease.

Strain HT-LYKH202F was a temperature-sensitive strain, whereas strains HTYT-ARL-AFP02F (isolated from an AFP patient) and HTYT-ARLH403F were not. All these 3 strains had high nucleotide and amino acid similarities with each other (a total of 8 nucleotide substitutions of which 6 caused amino acid substitutions), which implies that possibly one or several sites may play significant roles in this biological feature. Our research team is currently using reverse genetics methods to elucidate the mechanism of temperature sensitivity of HEV85, in order to identify several vaccine candidate strains to meet emergency needs in case of epidemic outbreaks triggered by these serotypes in the future.

Recently, increasing numbers of publications have demonstrated that recombination is extremely frequent among HEVs [@pone.0055480-Zhang1], [@pone.0055480-Zhang2], [@pone.0055480-Zhang3]. Therefore, it can be concluded that HEVs exist as a huge reservoir of genetic material comprising a limited quantity of capsid gene sets defining a finite number of serotypes and a range of non-structural genes that recombine frequently to produce new virus variants. The Chinese HEV85 strains identified in this study are no exception, and have recombined with other HEV-B viruses; this is supported by the genomic features, the phylogenetic tree based on the alignments of the *P1*, *P2*, *P3* regions, and the similarity and bootscan plots. Together with the isolation of HEV85, a recently identified novel HEV serotype, the trapping of an unknown new serotype HEV-B donor sequence in the Chinese HEV85 recombinant described in this study suggests that new HEV-B serotypes are in circulation in the Xinjiang region of China. Hence, we have increased HEV surveillance in the Xinjiang region in order to determine the precise donor sequence of the new serotype HEVs.

Identifying HEVs recovered from patient specimens has several implications in the medical field, and HEVs should be characterized to allow epidemiological surveillance of the potential epidemic risks associated with new viruses. Indeed, there are more and more novel HEV serotypes that exhibit some features pertaining to epidemic risk; for example, they were isolated from patients, show high prevalence in many regions, and even elicit epidemic outbreaks [@pone.0055480-Lewthwaite1]--[@pone.0055480-Piralla1]. Therefore, it is considered important to conduct stool surveys in the Xinjiang Autonomous Region, as a few AFP patients have been identified during AFP surveillance activities in support of global polio eradication. However, an effective HEV pathogen surveillance system has yet to be established in mainland China; therefore, current information on HEV85 or other novel HEV serotypes in circulation is not available. Once this is in place, it is expected that monitoring trends in the transmission of HEV85 or other new HEV types will be made possible by molecular epidemiological studies over a wide area. As more laboratories adopt molecular typing methods in order to identify newly described HEV serotypes, it will become possible to address the global distribution of HEV85 and to better understand its epidemiology, disease burden, and spectrum of illness.

Materials and Methods {#s4}
=====================

Viruses {#s4a}
-------

This study did not involve human participants or human experimentation; the only human materials used were stool samples collected from AFP patients or their close contacts at the instigation of the Ministry of Health P. R. of China for public health purposes, and written informed consent for the use of their clinical samples was obtained from all patients involved in this study. This study was approved by the second session of the Ethics Review Committee of the Chinese Center for Disease Control and Prevention. The HEV85 strains used in this study were isolated from stool specimens from one AFP patient and 32 of his healthy close contacts in the Hotan and Kashgar prefectures in the Xinjiang region of China. Viruses were isolated from original stool specimens by propagation in human rhabdomyosarcoma (RD) and human larynx carcinoma (HEp-2) cells by conventional methods and then sequenced [@pone.0055480-World1].

Determination of the complete *VP1* nucleotide sequence {#s4b}
-------------------------------------------------------

Viral RNA was extracted from the viral isolates using a QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA, USA). The complete *VP1*/capsid region of each HEV85 strain was amplified by reverse transcription-polymerase chain reaction (RT-PCR) using the primers described previously [@pone.0055480-Oberste4]. RT-PCR was performed with an Access RT-PCR Kit (Promega, Madison, Wisconsin, USA) according to the manufacturer\'s instructions. The PCR products obtained were purified using the QIAquick Gel extraction kit (Qiagen), and the amplicons were bi-directionally sequenced using an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Hitachi, Japan) [@pone.0055480-Zhang4].

Full-length genome sequencing of Chinese HEV85 strains {#s4c}
------------------------------------------------------

First of all, viral RNA was converted to cDNA by a random priming strategy. Then the complete genome sequences of the viruses were acquired according to the published strategies for HEV sequencing [@pone.0055480-Zhang2], [@pone.0055480-Sun1]. Briefly, the overlapping fragments representing the complete genomes were amplified by RT-PCR with the specific, non-degenerate primers listed in [Table 3](#pone-0055480-t003){ref-type="table"}, and the primer-walking strategy was used to close gaps as necessary. The PCR products obtained were purified for sequencing using the QIAquick Gel extraction kit (Qiagen), and the amplicons were then bi-directionally sequenced using fluorescent dideoxy-chain terminators and an ABI PRISM 3100 genetic analyzer (Applied Biosystems, Foster City, CA, USA). 5′-segment sequences were determined by using a 5′-rapid amplification of cDNA ends core set (Takara Biomedicals, Dalian, China), according to the manufacturer\'s instructions [@pone.0055480-Zhang2].

10.1371/journal.pone.0055480.t003

###### PCR and sequencing primers.

![](pone.0055480.t003){#pone-0055480-t003-3}

  Primer         Nucleotide position (nt)               Primer sequence (5′--3′)               Orientation         Reference
  ------------- -------------------------- -------------------------------------------------- ------------- -----------------------
  0001S48                                   GGGGACAAGTTTGTACAAAAAAGCAGGCTTTAAAACAGCTCTGGGGTT     Forward     [@pone.0055480-Yang1]
  HEV85-1049A           1030--1049                        ACAACAACATTGGCACACTC                   Reverse          This study
  HEV85-636S             636--655                         GCCATCCGGTGTCAAATAGA                   Forward          This study
  HEV85-1656A           1637--1656                        AGCCTGATCCGTGTAGTCCA                   Reverse          This study
  HEV85-1487S           1487--1506                        TGGGCAACCTAACGATCTTC                   Forward          This study
  HEV85-2640A           2611--2640                        GACTCTGAGCGGGAATGGTA                   Reverse          This study
  HEV85-2480S           2461--2480                        GAAGGGAGAGCGAGCCTAGT                   Forward          This study
  HEV85-3406A           3406--3425                        TAGTCCTCCCAGACGCAACT                   Reverse          This study
  HEV85-3290S           3268--3287                        CGTGCCACCATTAACACAGT                   Forward          This study
  HEV85-4257A           4238--4257                        TTCAATGGTGGCAATCTGAC                   Reverse          This study
  HEV85-4072S           4072--4091                        GGCTGGCTCAAGAAGTTCAC                   Forward          This study
  HEV85-5062A           5043--5062                        CTGGTGGACCTTGGAAAAGA                   Reverse          This study
  HEV85-4930S           4930--4949                        GCCATCCAGTTCATTGACAG                   Forward          This study
  HEV85-5880A           5861--5880                        GTTGCCACCAACGTGTATTC                   Reverse          This study
  HEV85-5722S           5722--5741                        TACATCCCCGTTGGTCAAGT                   Forward          This study
  HEV85-6619A           6600--6619                        GATGGCCGTCAAGCATAACT                   Reverse          This study
  HEV85-6436S           6436--6455                        GTGGCTAAAGGCAAGTCCAG                   Forward          This study
  HEV85-7260A           7241--7260                        TACTGGGACGCTCCTGATCT                   Reverse          This study
  HEV85-7084S           7084--7103                        CAATACCCCTTCCTCGTTCA                   Forward          This study
  7500A                                           GGGGACCACTTTGTACAAGAAAGCTGGG(T)~24~            Reverse     [@pone.0055480-Yang1]

Phylogenetic and Bioinformatics analyses {#s4d}
----------------------------------------

The nucleotide and deduced amino acid sequences of the HEV85 isolates were compared to one another and to those of other HEV-B serotypes by pairwise alignment using the MEGA program (version 5.0; Sudhir Kumar, Arizona State University, Tempe, Arizona, USA) [@pone.0055480-Tamura1], [@pone.0055480-Kumar1], and the identity matrices were analyzed by plotting VP1 amino acid identities versus *VP1* nucleotide identities for each virus pair using the SigmaPlot program (version 10.0; Systat Software Inc., San Jose, CA, USA). Phylogenetic trees were constructed by the neighbor-joining method implemented in the MEGA program using the Kimura-2-parameters model. Regions containing alignment gaps were omitted from the analysis. The branch lengths of the dendrogram were determined from the topologies of the trees and were obtained by majority rule consensus among 1000 bootstrap replicates. Bootstrap values greater than 80% were considered statistically significant for grouping.

Recombination analysis {#s4e}
----------------------

The nucleotide alignment containing the genome sequence of a Chinese HEV85 strain (HTYT-ARL-AFP02F) and HEV-B prototype strains (ECHO-1, 4, 6, 7, 9, 11, 13, 16, 18--21, 24, 27, 29, 30, 33, CVA9, CVB3--5, HEV69, HEV73--75, HEV77, 79--88, HEV97--98, HEV100--101, and HEV107) was generated using the MEGA program (version 5.0; Sudhir Kumar, Arizona State University, Tempe, Arizona, USA) [@pone.0055480-Tamura1], [@pone.0055480-Kumar1]. Once aligned, similarity plot and bootscan analyses were performed using Simplot program (version 3.5.1; Stuart Ray, Johns Hopkins University, Baltimore, Maryland, USA) [@pone.0055480-Lole1].

Assay for temperature sensitivity {#s4f}
---------------------------------

Temperature sensitivities of 3 selected HEV85 isolates (HT-LYKH202F, HTYT-ARLH403F and HTYT-ARL-AFP02F) were assayed on monolayer RD cells in 24-well plates as described before [@pone.0055480-Blomqvist1]. Briefly, the 24-well plates were inoculated with 50 µl of undiluted virus stocks. Two different incubators were used; the temperature of one incubator was adjusted to 36°C (optimal temperature for virus propagation), while the temperature of the other incubator was adjusted at 39.5°C (supraoptimal temperature for virus propagation). After absorption at 36°C or at 39.5°C for 1 h, the unabsorbed virus inoculum was removed, 100 µl of maintenance medium was added to each well, and the plates were continually incubated at 36°C or at 39.5°C, separately. After 5 time points post-infection (4, 8, 16, 24, and 48 h), the plates were harvested, and the cell culture infectious dose 50% (CCID~50~) was calculated by the end-point dilution method on monolayer RD cells in 96-well plates at 36°C. In this study, virus isolates showing more than a 2-logarithm reduction in titer at different temperatures were considered to be temperature-sensitive [@pone.0055480-Zhang1].

Nucleotide sequence accession numbers {#s4g}
-------------------------------------

The 5 full-length genomic sequences of HEV85 strains that were determined in this study have been deposited in the GenBank database under the accession numbers JX898905 to JX898909. The 28 other complete *VP1* nucleotide sequences (870 nucleotides) of HEV85 strains that were determined in this study have been deposited in the GenBank database under the accession numbers JX898910 to JX898937.
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